Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 04:04 ET | Source: Research and Markets

Systemic Mastocytosis Market Analysis and Forecast, 2025-2035 | Precision Medicine Gains Momentum as KIT D816V Mutation Detection Advances

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Systemic Mastocytosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added...
June 04, 2025 11:07 ET | Source: Association of American Physicians and Surgeons

Severe Allergic Reactions post Vaccination Discussed in Journal of American Physicians and Surgeons

Life-threatening allergies may be triggered by respiratory virus vaccines, such as influenza and COVID. Repeated doses may sensitize patients.
June 03, 2025 07:20 ET | Source: Research and Markets

Pollen Allergy Market Analysis Report 2025: Innovative Strategies in Pollen Allergy Diagnosis and Treatment Emerge - Global Forecast to 2030

Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pollen Allergy was valued...
May 07, 2025 04:03 ET | Source: Research and Markets

Chronic Spontaneous Urticaria Market Report 2025-2035: Industry Growth Accelerates with Rise in Biologic Therapies and Diagnostic Advancements

Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report...
December 12, 2024 10:05 ET | Source: Invea Therapeutics

Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors

GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...
May 16, 2023 04:43 ET | Source: Research and Markets

Allergy Conjunctivitis Global Market Report 2023: Rise in Air Pollutants and Chemicals Drives Growth

Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Allergy Conjunctivitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global allergy conjunctivitis market...
November 21, 2022 12:09 ET | Source: AB Science

AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier une étude confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer

COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...
November 21, 2022 12:09 ET | Source: AB Science

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...
October 10, 2022 12:04 ET | Source: AB Science

AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer

COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
October 10, 2022 12:04 ET | Source: AB Science

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...